Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
Acute Gouty Arthritis
About this trial
This is an interventional treatment trial for Acute Gouty Arthritis focused on measuring Pain, acute gout, arthritis, cyclooxygenase-2 inhibitors, lumiracoxib, indomethacin
Eligibility Criteria
Inclusion Criteria: Ambulatory cooperative male or female patients of at least 18 years of age With an acute attack of gout in 4 joints or less, diagnosed clinically according to the ACR 1977 classification criteria and with an onset within the last 48 hours prior to evaluation. Where more than one joint is involved, the most affected joint should be identified, as the study joint, at baseline and followed throughout the study Who present at Baseline with an acute pain intensity of at least moderate. Exclusion Criteria: With an acute attack of gout before the last 48 hours prior to evaluation With polyarticular gout involving > 4 joints With rheumatoid arthritis, infectious arthritis, pseudo-gout or other acute inflammatory arthritides. Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Novartis
- For Site Information, contact Novartis Pharma AG